KAN-004 for Colitis

This trial tests the safety of a new treatment called KAN-004, a potential drug for individuals with immune-related colitis, where the immune system attacks the colon, causing inflammation. Participants must have previously received treatment for a solid tumor with a specific cancer drug and now have colitis untreated by steroids. The trial requires participants who can swallow pills and are willing to provide blood and stool samples. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that KAN-004 has been studied for its safety in treating immune-related colitis. Researchers collected safety information from the start of treatment up to one year after stopping it, carefully monitoring for any side effects or problems over an extended period. However, since the trial is in an early stage, the full safety profile in humans is still being understood. Early trials primarily focus on ensuring a treatment's safety, so KAN-004 is expected to be generally well-tolerated. Nonetheless, rare or long-term side effects might not yet be fully known.¹²³⁴⁵

Unlike the standard treatments for colitis, which often rely on steroids to reduce inflammation, KAN-004 is being explored for its potential to help those who haven't used steroids before. Researchers are excited about KAN-004 because it may offer a new way to manage colitis without the typical side effects of steroids, such as weight gain and weakened bones. This drug could provide a more targeted approach to treating inflammation, potentially improving comfort and quality of life for patients.

Research has shown that KAN-004, the investigational treatment in this trial, produced promising results in early studies for treating immune-related colitis (irColitis), a type of bowel inflammation. In lab tests, KAN-004 reduced colitis symptoms and improved the body's ability to fight tumors. Researchers hope KAN-004 could enable patients to continue cancer treatment longer by easing colitis symptoms. Overall, these early findings suggest KAN-004 might effectively manage irColitis, but further studies are needed to confirm these results in people.¹⁶⁷⁸⁹